Age-related Macular Degeneration Drugs Market Growth Outlook and Strategic Analysis 2026 to 2035

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Age-related Macular Degeneration (AMD) Drugs Market Size, Share & Trends Analysis Report By Products (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, Other Products), Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Other Molecules), Type of AMD (Wet AMD, Dry AMD), Approval type (Biologic, Biosimilar) End User (Hospitals, Specialty Centers, Long-Term Care Facilities)- Market Outlook And Industry Analysis 2035"

Age-related Macular Degeneration (AMD) Drugs Market Size is valued at USD 11.21 Bn in 2025 and is predicted to reach USD 27.96 Bn by the year 2035 at an 9.7% CAGR during the forecast period for 2026 to 2035.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2854

Age-related Macular Degeneration (AMD) is a progressive ocular disorder primarily affecting older adults, resulting from degeneration of the macula, the central region of the retina responsible for sharp, detailed vision. AMD is typically classified into two primary forms: dry AMD, the more prevalent type characterized by gradual vision decline, and wet AMD, which involves rapid vision loss due to the development of abnormal subretinal blood vessels.

The AMD therapeutics market is predominantly driven by anti-vascular endothelial growth factor (anti-VEGF) therapies, including Eylea and Lucentis, which are primarily indicated for wet AMD. These treatments inhibit neovascularization, thereby slowing further vision loss. Recent innovations, such as Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), have begun addressing the unmet treatment needs in dry AMD, particularly in patients with geographic atrophy.

The clinical and commercial significance of AMD therapies lies in their ability to delay disease progression and preserve visual function. Market growth is supported by demographic trends, including an aging global population, increasing AMD prevalence linked to environmental and lifestyle factors, and ongoing advancements in ophthalmology. The emergence of new dry AMD therapies represents a key milestone in the sector, enhancing patient outcomes and overall quality of life. These developments underscore the expanding potential of the AMD treatment market to meet evolving clinical demands and population health priorities.

List of Prominent Players in the Age-related Macular Degeneration (AMD) Drugs Market:
• Regeneron Pharmaceuticals Inc. (US)
• Bayer AG (Germany)
• F. Hoffmann-La Roche AG (Switzerland)
• Novartis AG (Switzerland)
• Apellis Pharmaceuticals, Inc. (US)
• Coherus BioSciences, Inc. (US)
• Astellas Pharma Inc. (Japan)
• Biogen (US)
• STADA Arzneimittel AG (Germany)
• Formycon AG (Germany)
• Biocon. (India)
• Outlook Therapeutics, Inc. (US)
• Intas Pharmaceuticals Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Chengdu Kanghong Biotech Company (China)
• Sandoz Group AG (Switzerland)
• Stealth BioTherapeutics Inc. (US)
• Ocular Therapeutix, Inc. (US)
• Opthea Limited, Inc. (Australia)
• Kodiak Sciences Inc. (US)
• Innovent Biologics, Inc. (China)
• Bio-Thera Solution Inc. (China)
• Alvotech (Iceland)
• Alteogen Inc. (South Korea)
• Shanghai Henlius Biotech, Inc. (China)
• Amgen Inc. (US)
• Ocumension Therapeutics. (China)
• Adverum Biotechnologies, Inc. (US)

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The global Age-related Macular Degeneration (AMD) therapeutics market is experiencing sustained growth, driven by several key factors. Rising prevalence of AMD, particularly among aging populations, is closely associated with lifestyle-related risk factors such as poor diet, tobacco consumption, and sedentary behavior. Advances in drug development, including the introduction of novel therapies such as Pegcetacoplan (Syfovre) and Avacincaptad Pegol (IZERVAY) for dry AMD, along with longer-acting anti-VEGF agents for wet AMD, have expanded treatment options and enhanced clinical outcomes.

Improved reimbursement frameworks have further increased treatment accessibility and adherence. Additionally, emerging markets in the Asia-Pacific and Latin American regions present significant growth potential, supported by increased research and development investments. The trend toward personalized medicine, coupled with strategic collaborations between public and private sectors, is driving therapeutic innovation and enabling more targeted treatment approaches, thereby improving patient outcomes and sustaining market growth.

Challenges:
Despite positive momentum, the AMD therapeutics market faces significant challenges. The high cost of branded anti-VEGF treatments, such as Eylea and Vabysmo, can restrict patient access and adherence, prompting some patients to seek off-label alternatives. Furthermore, treatment options for dry AMD remain limited, with few approved pharmacologic therapies and continued reliance on nutritional supplements, constraining overall market expansion.

Regional Trends:
North America currently dominates the global AMD therapeutics market, supported by a well-established pharmaceutical research ecosystem and the presence of leading industry players and academic institutions. The region benefits from strong investment in research and development, facilitating the launch and regulatory approval of innovative treatments, including biosimilars such as Enzeevu for wet AMD.

Advanced healthcare infrastructure enables early diagnosis and effective disease management, while a favorable regulatory environment, exemplified by expedited review processes from the U.S. FDA, continues to foster market innovation. Comprehensive reimbursement systems and proactive collaboration between public and private entities further enhance treatment accessibility, drive product development, and reinforce North America's leading position in the global AMD therapeutics market.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2854

Recent Developments:
• In August 2023, Regeneron Pharmaceuticals announced that the U.S. FDA has approved EYLEA HD (aflibercept) 8 mg for treating wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).
• In March 2022, Novartis announced that the European Commission (EC) has approved Beovu® (brolucizumab) 6 mg for treating visual impairment due to diabetic macular edema (DME), marking its second EC-approved indication following wet age-related macular degeneration in 2020.

Segmentation of Age-related Macular Degeneration (AMD) Drugs Market-
By Products:
• Lucentis
• Eylea & Eylea HD
• Vabysmo
• Syfovre
• Other Products
By Molecules:
• Ranibizumab
• Aflibercept
• Faricimab
• Pegcetoplan
• Other Molecules
By Type of AMD:
• Wet AMD
• Dry AMD
By Approval type:
• Biologic
• Biosimilar
By End User:
• Hospitals
• Specialty Centers
• Long-Term Care Facilities
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/age-related-macular-degeneration-amd-drugs-market/2854

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.